Temperature Dependence of Plasmin-Induced Activation or Inhibition of Human Platelets

By He Lu, Claudine Soria, Elisabeth M. Cramer, Jeannette Soria, J. Maclouf, Jean Y. Perrot, Hong Li, Pierre L. Commin, Friedrich Schumann, Odile Regnier, Roger H. Lijnen, and Jacques P. Caen

It is known that at 37°C plasmin may have two opposite effects on platelets: at high concentrations (>1.5 clotting units [CU]/mL), plasmin activates platelets; at lower concentrations (0.1 to 1.0 CU/mL) it inhibits platelet activation induced by thrombin, collagen, or calcium ionophore A23187. In this study, we report that when lowering the incubation temperature to 22°C, plasmin at low concentrations (0.1 to 0.5 CU/mL) fully activated platelets. When platelets were treated with 0.2 CU/mL of plasmin, lowering the incubation temperature from 37°C to 22°C resulted in an increase in the expression of fibrinogen receptors, in platelet release and aggregation. Thromboxane A2 was not generated by plasmin treatment at either temperature. Ultrastructural studies showed that platelets responded to low-dose plasmin at 37°C by forming pseudopods, centralizing granules without fibrinogen release, whereas at 22°C the same dose of plasmin caused platelet degranulation with the appearance of α-granule fibrinogen within the lumen of the surface connected canalicular system. In addition, at 22°C plasmin at doses insufficient to induce platelet aggregation potentiates platelet response to thrombin. Thus, we suggest that plasmin may initiate both activating and inhibitory processes within platelets and that the change of temperature could influence this balance. These results may be of clinical relevance, because the fibrinolytic system was found activated during cardiopulmonary bypass in which the temperature of patient’s blood circulation was reduced. This temperature-dependent behavior is also an interesting model for a further study on platelet response to serine proteinases.

© 1991 by The American Society of Hematology.

PLASMIN IS a serine proteinase with a molecular weight of 85,000 daltons. It is derived from plasminogen activated by tissue-type plasminogen activator (t-PA) or urokinase (u-PA). As fibrin formation occurs, the fibrinolytic system becomes activated to promote fibrin dissolution. Studies during the last 2 decades have provided the evidence that the interaction between fibrinolytic enzymes and platelets is implicated in the regulation of hemostasis, thrombosis, and fibrinolysis. Several important mechanisms have been demonstrated. The binding of t-PA and of plasminogen to the platelet surfaces potentiates plasmin generation. t-PA and u-PA disperse preformed platelet aggregates. The activated platelets can release inhibitors both for PA and for plasmin. Furthermore, plasmin was shown to both activate platelets and inhibit platelet functions.

However, the mechanism through which plasmin affects platelets is not fully understood. The data in the literature suggest that plasmin has a variety of effects on platelets that depend both on the concentration of plasmin used and on the incubation time. At low concentrations (<1 clotting unit [CU]/mL), plasmin was reported to inhibit platelet activation in response to thrombin, collagen, and ionophore A23187. According to Schafer and Adelman, this inhibitory effect is related to an impairment of arachidonic acid metabolism without the involvement of cyclic adenosine monophosphate (cAMP) generation. They further reported that plasmin and prostaglandin I2 can synergistically inhibit platelet activation in response to thrombin and adenosine diphosphate (ADP). Using different techniques, Adnot et al reported that plasmin stimulates adenyl cyclase activity and suppresses the guanosine triphosphate (GTP)-dependent β-adrenergic inhibition in platelets. In contrast, at higher concentrations (>1.0 CU/mL) plasmin causes platelet aggregation accompanied by calcium mobilization, phosphorylation of 47-Kd and 20-Kd proteins, and activation of protein kinase C and phospholipase C. In addition, plasmin acts on glycoproteins on the platelet surface and reduces the interactions between platelet glycoprotein Ib and von Willebrand factor.

In our experiments we found that platelet activation by plasmin was dependent on the temperature at which washed platelets were incubated with plasmin. Temperature-dependent platelet aggregation and release reactions induced by plasmin were established between 37°C to 22°C. We show that at room temperature, plasmin concentrations below 0.1 CU/mL could induce strong platelet aggregation. In addition, treatment of platelets with plasmin at 22°C potentiated platelet activation by thrombin. The different platelet responses to plasmin according to the temperature could not be explained by the digestion either of fibrinogen receptor or of platelet fibrinogen. Therefore, we suggest that the activating processes in platelets induced by plasmin are counterbalanced by a temperature-dependent self-induced inhibitory process.

MATERIALS AND METHODS

Materials. Human fibrinogen (grade L) and purified plasmin (15 CU per milligram of protein, 1.27 CU/mL equal to 1 μmol/L)
were purchased from Kabi Laboratory (Stockholm, Sweden). The protein concentration in these preparations was measured using a protein assay kit (Sigma, St Louis, MO) with the Lowry procedure. Bovine thrombin (70 U/mg) was purchased from F. Hoffmann-La Roche Co Ltd (Basel, Switzerland). Aprotinin was from Bayer Parma (Paris, France). Biotin-N-hydroxysuccinimide ester was purchased from Calbiochem (San Diego, CA) and Streptavidin-phycocyanin was from Caltag Laboratory (San Francisco, CA). Recombinant hirudin was from Hoechst (Frankfurt, Germany).

Preparation of washed human platelets. Venous blood from healthy volunteers who had not taken aspirin or other medication known to interfere with the platelet function for at least 10 days before donation was collected into plastic tubes containing ACD buffer (6.8 mmol/L citric acid, 11.2 mmol/L trisodium citrate, 24 mmol/L glucose)\(^2\). The platelet-rich plasma (PRP) was obtained by centrifugation at 180 g for 10 minutes at room temperature. The platelet-rich plasma was subsequently centrifuged at 1,100 g for 10 minutes at room temperature and washed three times with the washing buffer (36 mmol/L citric acid, 5 mmol/L KCl, 2 mmol/L CaCl\(_2\), 1 mmol/L MgCl\(_2\), 103 mmol/L NaCl, 5 mmol/L glucose, pH 6.5) containing 3.5 mg/mL bovine albumin (Sigma), 7 mg/mL prostaglandin E\(_1\) (Sigma), and 25 \(\mu\)g/mL apyrase (Sigma). The washed platelets were resuspended in the reaction buffer (2 mmol/L KCl, 12 mmol/L NaHCO\(_3\), 0.3 mmol/L NaH\(_2\)PO\(_4\), 2.9 mmol/L CaCl\(_2\), 1 mmol/L MgCl\(_2\), 137 mmol/L NaCl, 5.5 mmol/L glucose, 3.5 mg/mL bovine albumin pH 7.35) before each assay.

Platelet aggregation. The washed platelets were resuspended to a final concentration of 4 to 5 x 10\(^9\)/mL in the reaction buffer. Plasmin-induced platelet aggregation was achieved by adding 20 \(\mu\)L of plasmin at various concentrations to 0.2 mL platelet suspension with or without incubation for 5 minutes at the indicated temperatures before stirring. The aggregation was monitored in an aggregometer (Chrono-log) at 37°C with stirring at 900 rpm. In some experiments, 10 to 20 \(\mu\)L of human fibrinogen (4 mg/mL) were added to the mixture. The aggregation induced by 0.5 U/mL thrombin was set up as a control. Maximal aggregation (%) was calculated as a percentage of the maximal intensity of platelet aggregation induced by thrombin (0.5 U/mL). Plasmin-induced platelet aggregation was totally inhibited by aprotinin at 0.2 \(\mu\)mol/L, showing that it depends on the active center of plasmin\(^2\).

Platelet aggregation induced by a combination of plasmin with thrombin was performed by incubating platelets for 5 minutes at 22°C with plasmin or with buffer, followed by adding thrombin to trigger aggregation with stirring. Final concentrations of plasmin and of thrombin used are indicated (see Fig 9).

Preparation of biotinylated monoclonal antibodies (MoAbs) and flow cytometric analysis. Murine AC1.2 MoAb (IgG\(_1\)), specific for PADGEM or GMP-140,\(^2\) was isolated from ascitic fluid by protein G affinity chromatography and dialyzed with the reaction buffer (0.2 mol/L NaHCO\(_3\), 0.15 mol/L NaCl, pH 8.8) overnight. Conjugation with biotin of the antibody was achieved by adding 0.1 mg biotin-N-hydroxysuccinimide ester in pure dimethyl sulfoxide to 1 mg dialyzed antibody in the reaction buffer. The reaction was stopped after 15 minutes of agitation at room temperature by adding 10% 1 mol/L NH\(_4\)Cl. Free biotin was removed by 24 hours dialysis with Tyrode buffer.

Conjugation with biotin of purified PAC-1 murine MoAb (IgM), which reacts with the fibrinogen receptor located on activated glycoprotein (GP) IIb/IIa complex on the platelet membrane,\(^2\) was performed as described above.

The binding assay for MoAbs to platelets was performed in Eppendorf tubes containing 50 \(\mu\)L Tyrode buffer and 5 \(\mu\)L biotinylated antibodies (7.7 \(\mu\)g/mL for PAC-1 and 0.6 \(\mu\)g/mL for AC1.2 as final concentration). If plasmin or thrombin was present in the samples, aprotinin (50 \(\mu\)g/mL) or hirudin (10 \(\mu\)g/mL) was included in Tyrode buffer to neutralize the respective enzymatic activities. Ten microliters of activated or resting platelets at 5 to 10 x 10\(^9\)/mL was then added into the tubes and incubated for 15 minutes at room temperature. Then, 10 \(\mu\)L of streptavidin-phycocyanin (PE) (1:5 diluted) was added to the mixture for another 15 minutes of incubation. The samples were then diluted with Tyrode buffer and fixed with an equal volume of phosphate-buffered saline (PBS) containing 10 mmol/L EDTA and 0.2% glutaraldehyde. Without further washing, the samples were directly analyzed in a Becton Dickinson (Sunnyvale, CA) FACStar flow cytometer with a matched computer. The platelets were distinguished from debris or "machine noise" and from red blood cells and white blood cells by setting the appropriate forward scatter and side scatter window with a side scatter threshold. PE fluorescence was detected with a 585/42 filter and fluorescence data were obtained with gain setting in the logarithmic mode. Activated platelets appeared in the same forward-side scatter window as nonactivated platelets. The microscopic examination of strongly fluorescent platelets sorted in the machine showed that more than 97% of activated platelets remained in individually separate forms. The expression of antigen on the platelet surface was represented as a mean channel number (MC) of platelet fluorescent intensity after the calculation with the computer program. The data were then calculated using the following formula for plotting:

\[
\text{Specific Fluorescence %} = \frac{\text{MC of Tested Sample} - \text{MC of Negative Control}}{\text{MC of Positive Control} - \text{MC of Negative Control}} \times 100
\]

Binding of PAC-1 and AC1.2 to platelets and differential releases of platelet granules. The release of the contents of \(\alpha\)-granules, dense granules, and lysosomes and the expression of both fibrinogen receptors and PADGEM on the platelet surface were simultaneously measured as a function of the plasmin concentration used to activate platelets. One part of ACD anticoagulated PRP was preincubated with \(^{14}C\)-serotonin at 0.6 \(\mu\)mol/L (0.37 kBq/mL PRP) for 30 minutes at room temperature. Then platelets were isolated and washed as mentioned above and resuspended in Tyrode buffer at a concentration of 1.6 x 10\(^9\)/mL. Three hundred microliters of platelets was incubated for 5 minutes (except for time-dependent experiments) with an equal volume of Tyrode buffer or plasmin solution at various concentrations. Then plasmin activity was inhibited by aprotinin at a final concentration of 50 \(\mu\)mol/L. Ten microliters of each sample was added to both PAC-1 and AC1.2 binding assay tubes as described above. EDTA (10 mmol/L) was added to the residual samples and these samples were immediately centrifuged at 4,000 g for 3 minutes for the quantifications in the supernatants of \(\beta\)-TG by enzyme-linked immunosorbent assay (Diagnostica Stago, Asnières, France) and N-\(\beta\)-acetyl glucosaminidase (NAG) activity.\(^2\) The amount of released \(\beta\)-TG and NAG was expressed as a percentage of the total content in the original platelet suspension lysed with 0.1% Triton X-100 (Touzart et Malignon, Vitry/Seine, France). After the treatment of \(^{14}C\)-serotonin preloaded platelets, 1% formaldehyde was added to stop the release and the platelets were centrifuged. The \(^{14}C\)-serotonin in the supernatants was counted and expressed as a percentage of the total amount of \(^{14}C\)-serotonin in the original platelet suspension.

Measurement of thromboxane \(B_2\). Washed platelets were exposed to plasmin at different temperatures for the indicated times. In some experiments, thrombin was added to plasmin-treated platelets followed by an incubation for another 3 minutes. After an agitation for 3 minutes, the reaction was stopped by the addition of EDTA at 10 mmol/L (final concentration) followed by an immedi-
ate centrifugation at 4°C. Then thromboxane B2 was measured in the supernatant with duplicate determinations as described.35

Electron microscopy. After the exposure of washed platelets to 0.2 CU/mL plasmin (or buffer for control) at 37°C or at 22°C for 5 minutes, platelets were first fixed by 1% glutaldehyde in Tyrode buffer, washed three times with PBS, and then alternatively post fixed with 1% osmium tetroxide, stained with uranyl acetate, and embedded in Epon (Ladd Research Industry, Burlington) for standard electron microscopy or embedded in glycol methacrylate for immunoelectron microscopy. Immunostaining for fibrinogen was performed on thin sections as described previously.36 These sections were observed under a Phillips 301 electron microscope.

RESULTS

Influence of temperature on plasmin-induced platelet aggregation. At 37°C plasmin at concentrations higher than 1 CU/mL induced only weak aggregation, whereas at 22°C plasmin at lower concentrations (0.5 to 1 CU/mL) induced an immediate and strong platelet aggregation. Moreover, when preincubating platelets for 5 minutes at 22°C with plasmin before stirring in the aggregometer cuvette, the concentration of plasmin that was needed to induce platelet aggregation was reduced even further. When different concentrations of plasmin were used to activate platelets for 5 minutes at 37°C or at 22°C two dose-dependent aggregation curves were obtained (Fig 1). When platelets were treated with a fixed concentration of plasmin, the occurrence and the intensity of aggregation was temperature dependent (Fig 2). The results in Fig 2 were not modified by the addition of aprotinin and fibrinogen (0.4 mg/mL) at the end of the incubation period, indicating that the absence of aggregation at 37°C was not due to the degradation of platelet fibrinogen by plasmin.

![Fig 1. Plasmin-induced platelet aggregation at 37°C and 22°C.](image1)

*Fig 1. Plasmin-induced platelet aggregation at 37°C and 22°C. Washed platelets (4 x 10⁹/mL) were kept at 37°C or 22°C in a water bath for 5 minutes, then were incubated with plasmin at the indicated final concentrations for another 5 minutes at the same temperature. Aprotinin was added at the end of incubation (100 µmol/L, final concentration). Aggregation was triggered by stirring. Means ± SD for eight different donors.

![Fig 2. Effect of temperature on plasmin-induced platelet aggregation.](image2)

**Fig 2. Effect of temperature on plasmin-induced platelet aggregation.** Washed platelets were preincubated at the indicated temperatures for 10 minutes. Then platelets (4 x 10⁹/mL) were incubated with a fixed final concentration of plasmin (0.2 CU/mL) for 5 minutes at the indicated temperatures. Aggregation was triggered by stirring. Means ± SD for eight different donors.

Influence of temperature on plasmin-induced platelet degranulation. The release reaction of platelet granules induced by plasmin was studied at different temperatures. The tests were performed at 22°C, 28°C, 32°C, and 37°C according to aggregation experiments. The results in Table 1 show that the release of serotonin from dense bodies and of N-β acetyl glucosaminidase activity from lysosomes was higher at 22°C than at 37°C. Similar results were noted for PADGEM expression (Fig 3): platelets incubated for 5 minutes at 37°C with 0.2 CU/mL plasmin did not express PADGEM on the platelet membrane, whereas full expression was shown when platelets were incubated with the same amount of plasmin at 22°C. When the incubation was performed at 32°C, the expression profile showed two peaks.

The results suggest that as the temperature decreased from 37°C to 22°C, the mechanism controlling the release of platelet granules and the expression of the fibrinogen receptor were progressively modified.

<table>
<thead>
<tr>
<th>Temperature (°C)</th>
<th>37°C</th>
<th>32°C</th>
<th>28°C</th>
<th>22°C</th>
</tr>
</thead>
<tbody>
<tr>
<td>¹⁴C-serotonin (%)</td>
<td>1.6 ± 1.3</td>
<td>1.9 ± 1.4</td>
<td>7.7 ± 2.3&lt;sup&gt;*&lt;/sup&gt;</td>
<td>9.9 ± 6.0&lt;sup&gt;*&lt;/sup&gt;</td>
</tr>
<tr>
<td>NAG (%)</td>
<td>0.4 ± 0.3</td>
<td>0.2 ± 0.7</td>
<td>1.8 ± 0.6&lt;sup&gt;*&lt;/sup&gt;</td>
<td>5.9 ± 0.7&lt;sup&gt;f&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Washed platelets were preincubated at the indicated temperatures for 5 minutes. Then they were incubated with 0.2 CU/mL of plasmin for another 5 minutes at the indicated temperatures. After a centrifugation, released ¹⁴C-serotonin and NAG in the supernatants were measured. The data were calculated as a percentage of the total amount released from triton-lysed original platelets. Means ± SD for four different donors. The significance of the difference between means was calculated by two-way analysis of variance.

<sup>*</sup>P < .05 to values obtained at 37°C.

<sup>f</sup>P < .01 to values obtained at 37°C.
EFFECT OF PLASMIN ON PLATELETS

Effect of plasmin on the binding of PAC-1 and AC1.2 to platelets and on the degranulation of platelets at 22°C. As plasmin degrades fibrinogen, the fibrinogen receptors induced by plasmin on platelets were studied with MoAb PAC-1, which recognizes specifically the fibrinogen receptors on GP IIb/IIIa. The amount of PAC-1 bound to the platelets treated with plasmin at 22°C was compared to the platelets activated with thrombin and ADP. The three agonists were added to the platelet suspension at relatively high concentrations to get maximal expression of fibrinogen receptors. Hirudin and aprotinin were added to neutralize thrombin and plasmin activities, respectively. As shown in Fig 4, the amount of PAC-1 bound to platelets activated by plasmin was similar to that induced by thrombin and much higher than that induced by ADP. This indicates that plasmin and thrombin are capable of inducing more fibrinogen-binding sites on platelets than ADP.

Figure 5 showed that platelets released their contents from α-granules (PADGEM expression), dense granules (serotonin), and lysosomes (NAG), and expressed fibrinogen-binding sites (PAC-1-binding sites) in response to plasmin at 22°C dose dependently. Expression of PADGEM correlated well to the curve of β-TG release (not shown). The binding of PAC-1 and AC1.2 MoAbs to platelets was found to be parallel during activation induced by plasmin at 22°C (Fig 6), suggesting that during platelet activation by plasmin at 22°C there was a large exposure of fibrinogen receptors on GP IIb/IIIa initially located in α-granules, as already described for thrombin-treated platelets.

Thromboxane B₂ synthesis by plasmin-treated platelets. It has been reported previously that plasmin does not induce thromboxane synthesis. Schäfer and Adelman¹⁴ found that the arachidonic acid metabolism of platelets was impaired by plasmin treatment, and they suggested that this impair-

Fig 3. Enhancement of plasmin-induced expression of PADGEM antigen on platelet surface by lowering the temperatures. Washed platelets were preincubated at the indicated temperatures for 10 minutes. Then platelets were incubated with plasmin (0.2 CU/ml) or Tyrode buffer for 5 minutes. Control nonactivated platelets (A); platelets treated with plasmin at 37°C (B), at 32°C (C), or at 22°C (D). Ten microliters of each sample was used for AC1.2 antibody-binding assay. Plasmin activity was neutralized by addition of aprotinin (final concentration, 50 μg/mL) in AC1.2 binding assay tubes. Ten thousand cells were analyzed in the flow cytometer.

Fig 4. Comparison of PAC-1 binding on the platelets activated by ADP, thrombin, and plasmin. Washed platelets (10⁹/ml) were incubated with Tyrode buffer (A), 40 μmol/L ADP (B), 2 U/ml thrombin (C), or 2 CU/ml plasmin (D) for 5 minutes at 22°C, then 10 μL of each sample was transferred to PAC-1 binding assay tubes, and 10,000 cells were analyzed in the flow cytometer. The indicated concentrations are the final concentrations.

Fig 5. Effect of plasmin at 22°C on the expression of fibrinogen receptors and PADGEM on platelet surface, and on the differential release of granules from platelets: dose-response curves. Three hundred microliters of washed platelet suspension (1.6 x 10⁹/ml) was incubated at 22°C for 5 minutes with 0.3 μL plasmin (final concentrations indicated). The platelets were tested for PAC-1 and AC1.2 binding by flow cytometric analysis as described in the Materials and Methods section. The amount of bound antibodies was presented as a percentage of the highest value (mean channel number) of fluorescent intensity obtained in platelets stimulated by 1.0 U/ml thrombin. After centrifugation, the supernatants were analyzed for ³⁵S-serotonin released from dense granules and for N-acetyl β-glucosaminidase activity released from lysosomes. The data for serotonin and NAG were obtained from triplicate determinations and were expressed as a percentage of the total amount released from a 0.1% Triton X-100-lysed sample of washed platelets. Similar results were obtained from two other repeated experiments.

For personal use only.on October 24, 2017. For personal use only.
ment was responsible for the inhibition of platelet response to thrombin, collagen, and A23187. We examined the thromboxane synthesis in plasmin-treated platelets at different temperatures. The results (Table 2) indicate that plasmin did not induce platelet thromboxane B2 generation at 37°C nor did it at 22°C. To further test the activity of the arachidonic acid metabolism in plasmin-treated platelets under our experimental conditions, thrombin was added to plasmin-treated platelets to induce thromboxane synthesis. The results in Table 3 show that plasmin did not reduce the thromboxane formation after thrombin stimulation.

Ultrastructural observation of platelets treated by plasmin at different temperatures. Electron microscopy observation of control platelets at 22°C and at 37°C showed no sign of degranulation. Others13-15 showed that thrombolytic agents were added. After agitation for 3 minutes in the aggregometer, the reaction was stopped by addition of EDTA at 10 mmol/L (final concentration), and the samples were centrifuged immediately. Thromboxane B2 was measured in the supernatants.

Table 2. Effect of Plasmin on Thromboxane B2 Generation at Different Temperatures

<table>
<thead>
<tr>
<th>Concentration (U/mL)</th>
<th>Thromboxane B2 (ng/10^9 platelets)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Normal Control</td>
</tr>
<tr>
<td>Thrombin 0</td>
<td>5.7 ± 7.2</td>
</tr>
<tr>
<td>Thrombin 0.06</td>
<td>36.4 ± 35.5</td>
</tr>
<tr>
<td>Thrombin 0.1</td>
<td>219.8 ± 49.2</td>
</tr>
<tr>
<td>Thrombin 0.4</td>
<td>1,688.0 ± 424.6</td>
</tr>
</tbody>
</table>

Washed platelets were preincubated with Tyrode buffer at 37°C were incubated with either 0.3 CU/mL plasmin or Tyrode buffer at 37°C for 15 minutes, then aprotinin (final concentration 10 μmol/L) and thrombin were added. After agitation for 3 minutes in the aggregometer, the morphology of platelets was different because apart from the emission of pseudopods, a process of degranulation was clearly shown: the channels of the surface connected canalicul system (SCCS) were filled with dense material, and a large number of platelets were almost empty (Fig 7D). Fibrinogen was restricted in α-granules (Fig 8A) and was absent in SCCS after plasmin treatment at 37°C. When platelets were treated with plasmin at 22°C, few fibrinogen-containing granules remained in the cytoplasm and a large amount of fibrinogen was present in the lumen of the SCCS (Fig 8B). However, dense bodies were often observed (Fig 8C).

Platelet aggregation induced by a combination of plasmin with thrombin. Plasmin-treated platelets at 37°C were shown to be resistant to thrombin activation.13,14 However, at 22°C pretreatment of platelets with plasmin at concentrations lower than that inducing platelet aggregation (0.01 CU/mL) potentiated platelet aggregation by thrombin (Fig 9A). The addition of thrombin (0.01 U/mL) also enhanced plasmin-induced platelet aggregation (Fig 9B).

DISCUSSION

The plasmin-induced platelet activation has been studied in vitro at different temperatures because platelets may be exposed to plasmin in a clinical condition, like open heart surgery using cardiopulmonary bypass.27 and in thrombolytic therapy.7 However, published results of in vitro studies indicate the inconsistent platelet responses to different concentrations of plasmin. Some investigators reported10,12 that plasmin induced platelet aggregation and degranulation. Others13-15 showed that thrombolytic agents
Fig 7. Ultrastructure of plasmin-treated platelets at different temperatures. Washed platelets were preincubated at the indicated temperatures for 5 minutes. Then platelets were incubated with plasmin (0.2 CU/mL) or buffer at the different temperatures for 5 minutes. (A) Control platelets at 37°C: they exhibit an even and regular elliptic shape and display numerous α-granules and scant SCCS (arrows); (B) control platelets at 22°C: they show uneven shape with few pseudopods (arrowheads); (C) platelets treated with plasmin at 37°C: signs of platelet activation, eg, numerous pseudopods (arrowheads) and granule centralization. The SCCS is empty (arrows); (D) platelets treated with plasmin at 22°C: platelet activation is intense with long and numerous pseudopods (arrowheads), less granules in the cytoplasm, and large SCCS cisternae filled with dense material (arrows). (Original magnification × 20,000.)
led to an inhibited platelet aggregation and degranulation in response to thrombin, ADP, collagen, and A23187.

Our experiments performed at 37°C confirm previous observations\(^{11,12}\); platelet aggregation did not occur when incubating washed platelets with plasmin at low concentrations (\(<1.0 \text{ CU/mL}\)) for 5 minutes, but did occur at plasmin concentrations higher than 1.0 CU/mL. However, we found that the change in the incubation temperature could modify the platelet response to plasmin stimulation as shown in Figs 1 and 2 with a temperature-dependent platelet aggregation, and in Table 1 showing a temperature-dependent release reaction. At 22°C with incubation, plasmin induced strong aggregation even at a low concentration (\(<0.1 \text{ CU/mL}\)). We also found that at 22°C plasmin potentiated platelet response to thrombin. The decrease in platelet response to plasmin at 37°C is not related to the digestion of platelet fibrinogen or of fibrinogen receptors by plasmin. These can be excluded for two reasons: Firstly, the addition of fibrinogen plus aprotinin in aggregation tests failed to induce aggregate formation of platelets pretreated with plasmin at 37°C. Secondly, the addition of fibrinogen into platelets that were treated with a high concentration of plasmin for at least 2 hours triggered perfect aggregation, indicating that fibrinogen receptors resisted plasmin digestion.\(^{13}\) Thus, these findings demonstrate for the first time that plasmin-induced platelet activation is temperature dependent.

Our experiments performed at 22°C showed a much stronger positive response of washed platelets to plasmin than those reported in the literature in which the studies were conducted at 37°C.\(^{11,12}\) At a concentration of plasmin below 1 CU/mL, we showed a dose-dependent platelet aggregation accompanied by an expression of fibrinogen receptors (PAC-1 binding) and by a release of α-granules with PADGEM expression, dense granules, and lysosomes. Furthermore, at 22°C the amount of fibrinogen receptors on platelets activated by plasmin was similar to that on platelets activated by thrombin and was much higher than that on platelets induced by ADP. The fibrinogen receptors on platelet-activated platelets could be detected at plasmin concentrations below 0.05 CU/mL. Thus, plasmin can probably induce the conformational change of GP IIb/IIIa when release reaction has not yet occurred. Further exposure of PAC-1 binding sites on platelet-activated platelets was noted at the higher concentrations of plasmin and accompanied by expression of PADGEM antigen on plate-
EFFECT OF PLASMIN ON PLATELETS

The results of the biologic assays were confirmed by ultrastructural observation with electron microscopy. The difference between platelets treated with the same low dose of plasmin at 37°C and 22°C was evident: at 22°C, platelet organelles were fused with the channels of the SCCS and a large amount of granules was extruded, as shown by the presence of fibrinogen in the lumen of the SCCS; at 37°C, only centralization of granules and few pseudopods were observed, but extrusion was rarely noticed. This observation suggests that the absence of platelet aggregation and the attenuated degranulation in response to low-dose plasmin at 37°C is related to an inhibited extrusion after centralization of granules.

Platelet aggregation is a complex process. The initiation of thromboxane synthesis in platelets is a common feedback pathway that provokes full activation. The results showed that the treatment of platelets by plasmin either at 37°C or at 22°C failed to induce the thromboxane generation, whereas a normal amount of thromboxane B$_2$ was obtained with plasmin-treated or nontreated platelets after thrombin stimulation. Thus, strong platelet activation induced by plasmin at 22°C was not mediated by the thromboxane B$_2$ pathway.

Taking our results and other published results together, we suggest that plasmin may initiate concomitantly both activating and inhibitory processes that are influenced by temperature. Adnot et al. found that plasmin may induce an elevation of the local cAMP concentration, indicating the possibility that cAMP is implicated in this inhibitory process.

Although full understanding of the biologic basis of plasmin-induced platelet activation and inhibition deserves further investigation, these results might help in understanding platelet activation during open-heart surgery using cardiopulmonary bypass (CPB). The hemostatic defect leading to heavy blood loss and prolonged postoperative bleeding in this type of surgery is a well-known clinical observation. A concomitant increase in fibrinolytic activity and platelet activation during CPB has been described. Activated platelets were detected using flow cytometric analysis during CPB. Our results lead us to suggest that platelet activation during CPB is related to the influence of temperature on platelet activation in response to generated plasmin, because the temperature of patient’s blood circulation using extracorporeal circulation (ECC) is maintained around 28°C to 32°C. Tanaka et al. related the decrease in platelet count to the activation of fibrinolysis and coagulation during CPB despite the use of heparin. Our results provide further evidence that platelets are more easily activated in the presence of generated plasmin plus thrombin at the temperature maintained during CPB. As a consequence, by exposure of the receptors for fibrin(ogen) and PADGEM antigen, which mediate adhesion of activated platelets to neutrophils and monocytes, these activated platelets may be quickly eliminated from the blood circulation.

In this context, the temperature-dependent influence of...
platelet activation induced by plasmin. This phenomenon bolytic agents) may reduce the rate of thrombolysis. To minimize the rate of reocclusion, the administration of proteinase inhibitor with strong plasmin-inhibiting capacity, effectively reduces blood loss in CPB.

Recently, attention has also been drawn to the role of plasmin in rethrombosis after thrombolytic therapy. Theoretically, one can suggest that platelet activation induced by a high local concentration of plasmin (generated by thrombolytic agents) may reduce the rate of thrombolysis. To minimize the rate of reocclusion, the administration of antiplatelet agents, including aspirin and prostaglandin E,

Recently, attention has also been drawn to the role of plasmin in rethrombosis after thrombolytic therapy. Theoretically, one can suggest that platelet activation induced by a high local concentration of plasmin (generated by thrombolytic agents) may reduce the rate of thrombolysis. To minimize the rate of reocclusion, the administration of antiplatelet agents, including aspirin and prostaglandin E,

Recently, attention has also been drawn to the role of plasmin in rethrombosis after thrombolytic therapy. Theoretically, one can suggest that platelet activation induced by a high local concentration of plasmin (generated by thrombolytic agents) may reduce the rate of thrombolysis. To minimize the rate of reocclusion, the administration of antiplatelet agents, including aspirin and prostaglandin E,

Recently, attention has also been drawn to the role of plasmin in rethrombosis after thrombolytic therapy. Theoretically, one can suggest that platelet activation induced by a high local concentration of plasmin (generated by thrombolytic agents) may reduce the rate of thrombolysis. To minimize the rate of reocclusion, the administration of antiplatelet agents, including aspirin and prostaglandin E,

Recently, attention has also been drawn to the role of plasmin in rethrombosis after thrombolytic therapy. Theoretically, one can suggest that platelet activation induced by a high local concentration of plasmin (generated by thrombolytic agents) may reduce the rate of thrombolysis. To minimize the rate of reocclusion, the administration of antiplatelet agents, including aspirin and prostaglandin E,

Recently, attention has also been drawn to the role of plasmin in rethrombosis after thrombolytic therapy. Theoretically, one can suggest that platelet activation induced by a high local concentration of plasmin (generated by thrombolytic agents) may reduce the rate of thrombolysis. To minimize the rate of reocclusion, the administration of antiplatelet agents, including aspirin and prostaglandin E,

Recently, attention has also been drawn to the role of plasmin in rethrombosis after thrombolytic therapy. Theoretically, one can suggest that platelet activation induced by a high local concentration of plasmin (generated by thrombolytic agents) may reduce the rate of thrombolysis. To minimize the rate of reocclusion, the administration of antiplatelet agents, including aspirin and prostaglandin E,

Recently, attention has also been drawn to the role of plasmin in rethrombosis after thrombolytic therapy. Theoretically, one can suggest that platelet activation induced by a high local concentration of plasmin (generated by thrombolytic agents) may reduce the rate of thrombolysis. To minimize the rate of reocclusion, the administration of antiplatelet agents, including aspirin and prostaglandin E,

Recently, attention has also been drawn to the role of plasmin in rethrombosis after thrombolytic therapy. Theoretically, one can suggest that platelet activation induced by a high local concentration of plasmin (generated by thrombolytic agents) may reduce the rate of thrombolysis. To minimize the rate of reocclusion, the administration of antiplatelet agents, including aspirin and prostaglandin E,

Recently, attention has also been drawn to the role of plasmin in rethrombosis after thrombolytic therapy. Theoretically, one can suggest that platelet activation induced by a high local concentration of plasmin (generated by thrombolytic agents) may reduce the rate of thrombolysis. To minimize the rate of reocclusion, the administration of antiplatelet agents, including aspirin and prostaglandin E,

Recently, attention has also been drawn to the role of plasmin in rethrombosis after thrombolytic therapy. Theoretically, one can suggest that platelet activation induced by a high local concentration of plasmin (generated by thrombolytic agents) may reduce the rate of thrombolysis. To minimize the rate of reocclusion, the administration of antiplatelet agents, including aspirin and prostaglandin E,

Recently, attention has also been drawn to the role of plasmin in rethrombosis after thrombolytic therapy. Theoretically, one can suggest that platelet activation induced by a high local concentration of plasmin (generated by thrombolytic agents) may reduce the rate of thrombolysis. To minimize the rate of reocclusion, the administration of antiplatelet agents, including aspirin and prostaglandin E,

Recently, attention has also been drawn to the role of plasmin in rethrombosis after thrombolytic therapy. Theoretically, one can suggest that platelet activation induced by a high local concentration of plasmin (generated by thrombolytic agents) may reduce the rate of thrombolysis. To minimize the rate of reocclusion, the administration of antiplatelet agents, including aspirin and prostaglandin E,

Recently, attention has also been drawn to the role of plasmin in rethrombosis after thrombolytic therapy. Theoretically, one can suggest that platelet activation induced by a high local concentration of plasmin (generated by thrombolytic agents) may reduce the rate of thrombolysis. To minimize the rate of reocclusion, the administration of antiplatelet agents, including aspirin and prostaglandin E,

Recently, attention has also been drawn to the role of plasmin in rethrombosis after thrombolytic therapy. Theoretically, one can suggest that platelet activation induced by a high local concentration of plasmin (generated by thrombolytic agents) may reduce the rate of thrombolysis. To minimize the rate of reocclusion, the administration of antiplatelet agents, including aspirin and prostaglandin E,

Recently, attention has also been drawn to the role of plasmin in rethrombosis after thrombolytic therapy. Theoretically, one can suggest that platelet activation induced by a high local concentration of plasmin (generated by thrombolytic agents) may reduce the rate of thrombolysis. To minimize the rate of reocclusion, the administration of antiplatelet agents, including aspirin and prostaglandin E,

Recently, attention has also been drawn to the role of plasmin in rethrombosis after thrombolytic therapy. Theoretically, one can suggest that platelet activation induced by a high local concentration of plasmin (generated by thrombolytic agents) may reduce the rate of thrombolysis. To minimize the rate of reocclusion, the administration of antiplatelet agents, including aspirin and prostaglandin E,

Recently, attention has also been drawn to the role of plasmin in rethrombosis after thrombolytic therapy. Theoretically, one can suggest that platelet activation induced by a high local concentration of plasmin (generated by thrombolytic agents) may reduce the rate of thrombolysis. To minimize the rate of reocclusion, the administration of antiplatelet agents, including aspirin and prostaglandin E,

Recently, attention has also been drawn to the role of plasmin in rethrombosis after thrombolytic therapy. Theoretically, one can suggest that platelet activation induced by a high local concentration of plasmin (generated by thrombolytic agents) may reduce the rate of thrombolysis. To minimize the rate of reocclusion, the administration of antiplatelet agents, including aspirin and prostaglandin E,

Recently, attention has also been drawn to the role of plasmin in rethrombosis after thrombolytic therapy. Theoretically, one can suggest that platelet activation induced by a high local concentration of plasmin (generated by thrombolytic agents) may reduce the rate of thrombolysis. To minimize the rate of reocclusion, the administration of antiplatelet agents, including aspirin and prostaglandin E,


37. ISIS-2 Collaborative Study Group: Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction-ISIS-2. Lancet 2:349, 1988


Temperature dependence of plasmin-induced activation or inhibition of human platelets

H Lu, C Soria, EM Cramer, J Soria, J Maclouf, JY Perrot, H Li, PL Commin, F Schumann and O Regnier